EP2773336A4 - Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent - Google Patents

Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Info

Publication number
EP2773336A4
EP2773336A4 EP11875114.8A EP11875114A EP2773336A4 EP 2773336 A4 EP2773336 A4 EP 2773336A4 EP 11875114 A EP11875114 A EP 11875114A EP 2773336 A4 EP2773336 A4 EP 2773336A4
Authority
EP
European Patent Office
Prior art keywords
halofenate
urate
gout
patients
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11875114.8A
Other languages
German (de)
French (fr)
Other versions
EP2773336A1 (en
Inventor
Brian K Roberts
Gopal Chandra Saha
Brian Edward Lavan
Charles A Mcwherter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diatex Inc
CymaBay Therapeutics Inc
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of EP2773336A1 publication Critical patent/EP2773336A1/en
Publication of EP2773336A4 publication Critical patent/EP2773336A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11875114.8A 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent Withdrawn EP2773336A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Publications (2)

Publication Number Publication Date
EP2773336A1 EP2773336A1 (en) 2014-09-10
EP2773336A4 true EP2773336A4 (en) 2015-06-03

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11875114.8A Withdrawn EP2773336A4 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Country Status (13)

Country Link
EP (1) EP2773336A4 (en)
JP (1) JP6202633B2 (en)
KR (1) KR20140121383A (en)
CN (2) CN109908124A (en)
AU (1) AU2011380507B2 (en)
CA (1) CA2859686C (en)
CL (1) CL2014001155A1 (en)
IL (1) IL232386A0 (en)
MX (1) MX357507B (en)
NZ (1) NZ624708A (en)
SG (1) SG11201402032RA (en)
WO (1) WO2013066349A1 (en)
ZA (1) ZA201403575B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836209A4 (en) * 2012-04-13 2015-11-25 Cymabay Therapeutics Inc Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6368756B2 (en) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Method of treating hyperuricemia in patients suffering from gout using halofenate or halofenic acid and a second uric acid lowering drug
CN108014108A (en) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 The application of lesinurad or its pharmaceutically acceptable salt in the medicine for treating or preventing Cushing syndrome is prepared
US11446317B2 (en) 2017-10-26 2022-09-20 Otsuka Pharmaceutical Co., Ltd. Inositol phosphate-containing composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT01399008 on 2011_07_20: ClinicalTrials.gov Archive", 20 July 2011 (2011-07-20), XP055185403, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01399008/2011_07_20> [retrieved on 20150423] *
ANONYMOUS: "NCT01416402 on 2011_10_21: ClinicalTrials.gov Archive", 21 October 2011 (2011-10-21), XP055185406, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01416402/2011_10_21> [retrieved on 20150423] *
GOPAL C SAHA ET AL: "Arhalofenate, a Potential Novel Treatment for Hyperuricemia, with or without Metabolic Co-Morbidities, in Patients with Gout: Meta-Analysis of Urate Lowering in Four Phase 2 Studies in Type 2 Diabetes.", ARTHRITIS & RHEUMATISM, vol. 63, no. 10, Suppl. S, October 2011 (2011-10-01), pages S1014, XP055185501 *
HOWARD S SMITH ET AL: "Gout: Current Insights and Future Perspectives", JOURNAL OF PAIN, vol. 12, no. 11, 28 September 2011 (2011-09-28), pages 1113 - 1129, XP028334440, ISSN: 1526-5900, [retrieved on 20110704], DOI: 10.1016/J.JPAIN.2011.06.009 *
See also references of WO2013066349A1 *

Also Published As

Publication number Publication date
ZA201403575B (en) 2015-11-25
CN104066427A (en) 2014-09-24
EP2773336A1 (en) 2014-09-10
MX2014005400A (en) 2015-02-12
CA2859686C (en) 2018-09-11
JP6202633B2 (en) 2017-09-27
CL2014001155A1 (en) 2015-01-16
JP2014532758A (en) 2014-12-08
MX357507B (en) 2018-07-12
NZ624708A (en) 2015-11-27
KR20140121383A (en) 2014-10-15
AU2011380507B2 (en) 2017-06-15
CA2859686A1 (en) 2013-05-10
IL232386A0 (en) 2014-06-30
SG11201402032RA (en) 2014-09-26
CN109908124A (en) 2019-06-21
WO2013066349A1 (en) 2013-05-10
AU2011380507A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
HRP20180780T1 (en) Treatment of gout and hyperuricemia
EP2716669A4 (en) Surface-modifying method and elastic body with modified surface
EP2627331A4 (en) Methods for treating hyperuricemia and related diseases
EP2788075A4 (en) Device and method for reducing patient transthoracic
PT3257546T (en) Method of preparing a ready-to-use urinary catheter and a catheter assembly for use in said method
SG11201401811WA (en) Method for preventing and/or treating insulin resistance
AP2015008931A0 (en) Benzothiazole compounds and their pharmaceutical use
PT2663864T (en) Immunodiversity assessment method and its use
ZA201307742B (en) Method for manufacturing and utilizing ferritic-austenitic stainless steel
EP2739352A4 (en) Multi-modal electrotherapy method and apparatus
PT2717692T (en) Tetrahydrocannabinol-11-oic acids for use in treating fibrotic diseases
DK2750705T3 (en) Methods for effectively and rapidly desensitizing allergic patients
PL2413718T3 (en) Use of arachidonic acid for the reduction of the risk of insulin resistance later in life
ZA201403575B (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
SG11201401272RA (en) Method for manufacturing acrylic acid-based polymer and use for same
IL232385A (en) Use of the compounds halofenate or halofenic acid in the manufacture of medicaments for treating hyperuricemia in patients with gout, hyperuricemia or impaired renal function
HK1204913A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an antiinflammatory agent
EP2640376A4 (en) Caffeic acid derivatives and their use in improving neuronal cell viability
SG10201609202PA (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
EP2720703A4 (en) Methods for increasing insulin sensitivity and treating diabetes
EP2773261A4 (en) Manometer for use in testing spinal region and related method
GB201003894D0 (en) Inhibitors of glucose metabolism for use in the treatment of Birt-Hogg-Dubé syndrome
EP2548935A4 (en) Desulfurizing agent and manufacturing method therefor
GB201008519D0 (en) Method and apparatus for restricting ectoparasite infection in fish within a fish pen
EP2768536A4 (en) Method for treating type i and type ii diabetes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/19 20060101AFI20150428BHEP

Ipc: A61K 31/426 20060101ALI20150428BHEP

Ipc: A61P 19/06 20060101ALI20150428BHEP

Ipc: A61K 31/519 20060101ALI20150428BHEP

Ipc: A61K 31/216 20060101ALI20150428BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CYMABAY THERAPEUTICS, INC.

Owner name: DIATEX, INC.

17Q First examination report despatched

Effective date: 20180115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190603